Your browser doesn't support javascript.
SARS-CoV-2 Circulation during the First Year of the Pandemic: A Seroprevalence Study from January to December 2020 in Tuscany, Italy.
Marchi, Serena; Lanave, Gianvito; Camero, Michele; Dapporto, Francesca; Manenti, Alessandro; Benincasa, Linda; Acciavatti, Angela; Brogi, Giulio; Viviani, Simonetta; Montomoli, Emanuele; Trombetta, Claudia Maria.
  • Marchi S; Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.
  • Lanave G; Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy.
  • Camero M; Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy.
  • Dapporto F; VisMederi Srl, 53100 Siena, Italy.
  • Manenti A; VisMederi Srl, 53100 Siena, Italy.
  • Benincasa L; VisMederi Research Srl, 53100 Siena, Italy.
  • Acciavatti A; NeoMedica Srl, 53100 Siena, Italy.
  • Brogi G; NeoMedica Srl, 53100 Siena, Italy.
  • Viviani S; Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.
  • Montomoli E; Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.
  • Trombetta CM; VisMederi Srl, 53100 Siena, Italy.
Viruses ; 14(7)2022 06 30.
Article in English | MEDLINE | ID: covidwho-1917788
ABSTRACT
Italy was the second country affected by the SARS-CoV-2 pandemic; the virus spread mainly in Northern Italy with a subsequent diffusion to the center and southern part of the country. In this study, we aimed to assess the prevalence of antibodies against SARS-CoV-2 in the general population of the Siena province in the Tuscany region (Central Italy) during 2020. A total of 2480 serum samples collected from January to December 2020 were tested for IgM and IgG antibodies against SARS-CoV-2 by a commercial ELISA. Positive and borderline samples were further tested for the presence of anti-receptor-binding domain (RBD) IgM and IgG antibodies by an in-house ELISA and by a micro-neutralization assay. Out of the 2480 samples tested by the commercial ELISA, 81 (3.3%) were found to be positive or borderline for IgG and 58 (2.3%) for IgM in a total of 133 samples (5.4%) found to be positive or borderline for at least one antibody class. When the commercial ELISA and in-house ELISA/micro-neutralization assay results were combined, 26 samples (1.0%) were positive for RBD IgG, 11 (0.4%) for RBD IgM, and 23 (0.9%) for a neutralizing antibody. An increase in seroprevalence was observed during the year 2020, especially from the end of summer, consistent with the routine epidemiological surveillance of COVID-19 cases.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: V14071441

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: V14071441